by Peter Ciszewski | Mar 18, 2019
Dan O’Connor, President, Director and Chief Executive Officer of OncoSec discusses the KEYNOTE-890 study, a Phase 2 trial for the treatment of late-stage triple negative breast cancer (TNBC) with TAVO (intratumoral plasma encoded IL-12, or tavokinogene...
by Peter Ciszewski | Mar 14, 2019
Benjamin Forred, Translational Research Project Manager at Sanford Health in Sioux Falls, South Dakota, discusses his organization which is one of the largest health systems in the United States, including research into rare diseases. Sanford Health provides...
by Peter Ciszewski | Mar 13, 2019
Dan O’Connor, President, Director and Chief Executive Officer of OncoSec discusses the KEYNOTE-695 Study of TAVO + Keytruda in refractory metastatic melanoma. In this video, Mr. O’Connor provides an update regarding tumor responses in its...
by Peter Ciszewski | Mar 12, 2019
Dean Suhr, President of the MLD Foundation, provides an overview of Metachromatic leukodystrophy (MLD) and his advocacy organization focused on this rare disease. The MLD Foundation is a non-profit US tax-exempt organization that was formed in 2001 to serve...
by Peter Ciszewski | Mar 11, 2019
Ron Philip, Chief Commercial Officer of Spark Therapeutics, discusses gene testing for inherited eye diseases, including his company’s initative EyeWant2Know.com. Inherited retinal diseases are a group of rare eye disorders caused by an inherited gene...
